NCT00973479 – A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, an Anti-TNFalpha Monoclonal Antibody, Administered Intravenously, in Patients With Active Rheumatoid Arthritis Despite Methotrexate Therapy Posted on June 23, 2016 by tsuperadmin -
NCT00269854 – A Placebo-Controlled, Dose-Ranging Study Followed by a Placebo-Controlled, Repeated-Dose Extension of Anti-TNF Chimeric Monoclonal Antibody (cA2) in the Treatment of Patients With Active Crohn’s Disease Posted on June 15, 2016 by tsuperadmin -
NCT01190839 – Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial Comparing REMICADE (Infliximab) and Placebo in the Prevention of Recurrence in Crohn’s Disease Patients Undergoing Surgical Resection Who Are at Increased Risk of Recurrence Posted on June 15, 2016 by tsuperadmin -
NCT00236431 – A Randomized Double-Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer’s Disease Posted on June 8, 2016 by tsuperadmin -
NCT00236574 – A Randomized Double Blind Placebo-Controlled Trial to Evaluate the Efficacy and Safety of Galantamine in Patients With Mild Cognitive Impairment (MCI) Clinically at Risk for Development of Clinically Probable Alzheimer’s Disease Posted on June 8, 2016 by tsuperadmin -
NCT00253214 – Placebo-Controlled Evaluation of Galantamine in the Treatment of Alzheimer’s Disease: Safety and Efficacy of a Controlled-Release Formulation Posted on June 8, 2016 by tsuperadmin -
NCT00253188 – Efficacy, Tolerability and Safety of Galantamine in the Treatment of Alzheimer’s Disease Posted on June 8, 2016 by tsuperadmin -
NCT00261573 – The Safety and Efficacy of Galantamine in the Treatment of Vascular and Mixed Dementia Posted on June 8, 2016 by tsuperadmin -
An open-label, long-term study of risperidone for the treatment of behavioral disturbances in patients with dementia Posted on May 9, 2016 by tsuperadmin -
NCT00524043 – A Randomized, Double-Blind, Placebo- and Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of a Fixed Dosage of 1.5 mg/Day of Paliperidone Extended Release (ER) in the Treatment of Subjects With Schizophrenia Posted on March 31, 2016 by tsuperadmin -
The YODA Project